An artificial intelligence approach to variant calling of ALK resistance mutations.

Jochen K. Lennerz,Emily Chin,Marguerite Rooney,Michael G. Zomnir,Enrique Dominguez Meneses,Lev Lipkin,A. John Iafrate,Long P. Le,Alice T. Shaw

An artificial intelligence approach to variant calling of ALK resistance mutations.

2019

Jochen K. Lennerz
Emily Chin
Marguerite Rooney
Michael G. Zomnir
Enrique Dominguez Meneses
Lev Lipkin
A. John Iafrate
Long P. Le
Alice T. Shaw

3079Background: ALK tyrosine kinase inhibitors (TKIs) are effective in treating advanced anaplastic lymphoma kinase (ALK) fusion-positive non-small-cell lung cancers (NSCLC), and specific ALK varia...

Keywords:

Computational biology
Pathology
Medicine
Cancer research
Tyrosine kinase
Anaplastic lymphoma kinase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations